Ground Breaking Studies: Nattokinase is an Effective and Safe Natural Treatment for Patients with Vascular Disease and Patients with Ischemic Stroke and Transient Ischemic Attacks
In a groundbreaking study published in 2021, nattokinase was able to safely and effectively improve clinical symptoms of patients admitted to vascular surgery without the development of adverse drug reactions or drug interactions. In the study, subjects were divided into three groups: patients with deep vein thrombosis and treated with fondaparinux plus nattokinase (Group 1), patients with phlebitis treated with enoxaparin plus nattokinase (Group 2), patients with venous insufficiency after classical surgery and treated with nattokinase one day later (Group 3). In all three groups, there was statistically significant improvement in clinical symptoms in patients after 30 days of nattokinase administration (100mg/day). In all patients, there was also the absence of adverse drug reaction or interaction with nattokinase.
In another recent study published in 2020, nattokinase was prescribed for patients with ischemic stroke and transient ischemic attack (TIA) who underwent treatment. The nattokinase group was compared with a control group of patients with stroke and TIA in which secondary prevention was based on the antithrombotic drugs ASA and/or Clopidogrel. After monitoring both groups at 1, 3 and 6 month intervals, no statistically significant differences were observed in subsequent cerebrovascular accidents and vascular complications. These results show potential for use of nattokinase as an effective and safe secondary prevention treatment of ischemic stroke and TIA, especially for those that may show resistance to the commonly prescribed drugs ASA and Clopidogrel.
The safety and efficacy of nattokinase supplementation for cardiovascular health has long been confirmed and documented. In an extensive list of clinical and experimental studies, nattokinase has shown its efficacy in degrading blood clots, reducing high blood pressure, improving blood circulation, improving the clumping of platelet and red blood cells, and more. Nattokinase is already widely consumed as a dietary supplement for cardiovascular health, and these two recent studies show potential for use of nattokinase in the prevention and treatment of diseases such as vascular disease and ischemic stroke and TIA.
The mentioned studies were published in the journal Nutrients on June 13, 2021 under the title, “Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases” and in the journal Neurology and Neuroscience on May 25, 2020 under the title, “Use of Nattokinase in patients with ischemic stroke and transient ischemic attacks.”
